European Specialty Pharma is the Focus for Novo Growth Equity - Again
Novo's $30 million investment in Orexo, following its $60 million financing of Archimedes, shows appeal of European specialty pharma.
Novo's $30 million investment in Orexo, following its $60 million financing of Archimedes, shows appeal of European specialty pharma.